Design Therapeutics (DSGN) Net Cash Flow (2020 - 2026)

Design Therapeutics has disclosed Net Cash Flow across 7 years of filings, most recently posting -$4.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$4.1 million, up 54.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$897000.0 (up 94.3% YoY), and the FY2025 annual result was -$5.7 million, down 518.71% from the prior year.
• Net Cash Flow came in at -$4.1 million for Q1 2026 at Design Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $16.3 million in Q2 2024 to a low of -$167.7 million in Q2 2022.
• The 5-year median for Net Cash Flow is -$4.6 million (2025), against an average of -$16.8 million.
• Peak annual rise in Net Cash Flow reached 994.73% in 2024, while the deepest fall reached 2163.22% in 2024.
• Design Therapeutics' Net Cash Flow stood at -$16.0 million in 2022, then soared by 57.91% to -$6.7 million in 2023, then decreased by 15.17% to -$7.8 million in 2024, then surged by 122.77% to $1.8 million in 2025, then plunged by 331.11% to -$4.1 million in 2026.
• The last three Net Cash Flow figures came in at -$4.1 million (Q1 2026), $1.8 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.